Panel discussion

Date:April 22, 2024

Panel title

Achieve initial market access in Switzerland.

Panel summary

Is initial market authorisation in neurology and oncology worth it in Switzerland?
The most critical and mandatory prerequisites for Switzerland as a biotech startup innovation location are discussed.
Join and discuss with us.

Speaker information


Stephan Klapproth, Entrepreneur, Journalist and Moderator, former TV-Moderator


Dr. med. Carlos Beat Quinto, Member of the FMH central board
Dr. Peter Halbherr, Chairman and General Manager, InnoMedica
Further panelists TBA

Company profile

InnoMedica’s vision is to replace the systemic application of drugs with a targeted, and therefore gentler, approach by refining the most effective active ingredients into intelligent therapies using liposomal nanotechnology. The mission is therefore to enhance therapies for diseases with great therapeutic need, such as cancer, Parkinson’s or ALS, or to make therapy possible in the first place, in order to achieve real medical progress for the people affected.